Pharmaceutical Technology

JULY 4, 2022

GlaxoSmithKline (GSK) has completed the acquisition of all outstanding shares of US-based Sierra Oncology in a deal totalling $1.9bn (£1.6bn), in cash. In April this year, GSK entered an agreement for the acquisition of Sierra Oncology for $55 per share. Sierra develops targeted treatments for rare kinds of cancer.

Vaccination 306

Vaccination Vaccine Medicine Drugs 306

Pharmaceutical Technology

SEPTEMBER 11, 2023

Coherus BioSciences has concluded the acquisition of immuno-oncology (I-O) company Surface Oncology in a deal totalling nearly $66.9m.

162

162

Pharmaceutical Technology

MARCH 26, 2024

Nuvation Bio has entered into a definitive agreement to acquire AnHeart Therapeutics in a strategic move to bolster its oncology pipeline.

130

130

Bio Pharma Dive

JULY 11, 2022

Phase three oncology studies have approximately a 35% likelihood of leading to regulatory approval.

Trials 343

Trials 343

Pharmaceutical Technology

MARCH 27, 2024

We analyze the biggest trends in oncology and the technological solutions available to CROs to optimize efficiencies. CROs are fundamental to the development of cancer treatments but face multiple challenges.

Clinical Trials 130

Clinical Trials Clinical Trials Trials Development 130

Pharmaceutical Technology

JANUARY 4, 2024

BridGene has entered into a strategic partnership and licensing deal with Galapagos for the discovery of drug candidates for oncology targets.

Drugs 147

Drugs Licensing Licensing 147

Pharmaceutical Technology

JANUARY 30, 2024

Gilead Sciences and Arcus Biosciences have expanded their oncology partnership agreement and announced an equity investment.

130

130

Pharmaceutical Technology

DECEMBER 20, 2023

AI is delivering hugely promising results in oncology, from enhancing drug development to improving the detection of early-stage cancers.

Development 130

Development Drugs 130

Pharmaceutical Technology

FEBRUARY 16, 2024

Xyphos Biosciences has entered an agreement with Kelonia Therapeutics to develop immuno-oncology therapeutics for $875m.

Development 130

Development Drugs 130

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology: Leading companies in cancer monoclonal antibody therapy. The company is largely involved in immuno-oncology.

Antibody 261

Antibody Immune Response Protein Development 261

Pharmaceutical Technology

OCTOBER 5, 2023

Shorla Oncology has received $35m in Series B funding to boost the oncology portfolio growth by advancing its pipeline of drug candidates.

Drugs 130

Drugs 130

Pharmaceutical Technology

JANUARY 11, 2024

Pauline Frank reflects on her talk at the 2023 CTO Europe conference and highlights some of the key issues in running oncology trials.

Trials 130

Trials 130

Pharmaceutical Technology

JANUARY 22, 2024

An analysis of GlobalData’s analyst consensus sales and forecast database reveals that three out of 12 novel oncology brands that launched globally from November 2022 to December 2023 have the potential to reach blockbuster sales.

Branding 130

Branding Sales 130

World of DTC Marketing

SEPTEMBER 18, 2020

IN SUMMARY: According to a Takeda Oncology report “for people diagnosed with multiple myeloma, there can be an abundance of information, which can lead to confusion around the next steps in their diagnosis and treatment plan. Oncology DTC needs to distinguish the key benefits of products in terms that patients will understand.

Production 259

Production Engineer Doctors Doctor 259

ProRelix Research

FEBRUARY 20, 2024

Crafting impactful oncology clinical trial protocols requires a strategic approach to ensure rigorous research, patient safety, and meaningful outcomes.

Clinical Trials 97

Clinical Trials Clinical Trials Trials Research 97

Pharmaceutical Technology

OCTOBER 16, 2023

On October 9, Bristol Myers Squibb announced it had an agreement to acquire Mirati Therapeutics, a targeted oncology biotech company.

162

162

Pharmaceutical Technology

MAY 25, 2023

Pyxis Oncology has made a definitive agreement to buy biopharmaceutical company Apexigen, in a deal valued at nearly $16m. Pyxis Oncology will issue 0.1725 shares of its common stock, with par value of $0.001 per share, for each Apexigen share.

Antibody 130

Antibody Clinical Trials Clinical Trials Clinical Development 130

Pharmaceutical Technology

NOVEMBER 10, 2023

Bayer has expanded a drug discovery research partnership with Recursion Pharmaceuticals in the precision oncology sector.

Research 130

Research Drugs 130

Pharmaceutical Technology

JANUARY 17, 2024

In a report, findings suggested that cancer patients in the Netherlands will face longer waits to access new oncology medicines.

Medicine 130

Medicine Marketing 130

Pharmaceutical Technology

FEBRUARY 9, 2023

ReviR Therapeutics has signed a research collaboration and option-to-license agreement with Asieris Pharmaceuticals to discover new oncology therapeutics. Its initial focus is to develop therapeutics in oncology, CNS, and genetically defined disease indications.

Development 241

Development RNA Gene Therapy Genetics 241

Pharmaceutical Technology

NOVEMBER 8, 2023

Dewpoint Therapeutics and Evotec have partnered for the research and development of oncology programmes comprising c-mods.

Development 130

Development Drugs Research 130

Bio Pharma Dive

JUNE 16, 2023

Best known for its work in biosimilars, Coherus will acquire two drugs in human testing for various solid tumors through a roughly $65 million buyout of Surface Oncology.

Drugs 148

Drugs 148

Pharmaceutical Technology

JANUARY 24, 2024

AUR-105 is under clinical development by Aurigene Oncology and currently in Phase I for Leukemia.

Clinical Development 130

Clinical Development Development 130

Pharmaceutical Technology

NOVEMBER 14, 2023

MBrace Therapeutics has secured $85m in a Series B funding round to advance clinical development of ADCs for oncology targets.

Development 130

Development Clinical Development 130

Pharmaceutical Technology

NOVEMBER 7, 2023

At the BIO-Europe conference, experts said smaller oncology biotechs need to explore alternate financing strategies for pipeline development.

Development 130

Development 130

Pharmaceutical Technology

JULY 26, 2023

Roche’s anti-VEGF monoclonal antibody Avastin (bevacizumab) is one of the most successful oncology drugs of all time.

Antibody 130

Antibody Drugs 130

Pharmaceutical Technology

DECEMBER 5, 2023

Discussions at the 10th CTO Europe conference reflected old and new challenges that add pressure on companies running oncology trials.

Trials 130

Trials 130

Pharmaceutical Technology

FEBRUARY 15, 2023

In the last three years alone, there have been over 633,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Immuno-oncology in Pharmaceuticals: Gene therapy delivery using viral vectors.

Gene Therapy 246

Gene Therapy Gene Genome Genomics 246

Pharmaceutical Technology

SEPTEMBER 28, 2023

Ono Pharmaceutical and Adimab have signed a drug discovery collaboration agreement for the development of antibody drugs in oncology

Antibody 130

Antibody Development Drugs 130

XTalks

JANUARY 17, 2024

Oncology is recognized as having the largest drug pipeline of any therapeutic area. There are many aspects of oncology drug development that are driven by the unique nature of the treatments being developed and the needs of the patients, their caregivers and the doctors that treat them.

Clinical Trials 124

Clinical Trials Clinical Trials Trials Gene Therapy 124

Pharmaceutical Technology

MARCH 20, 2023

Predictive Oncology and Cancer Research Horizons, a part of Cancer Research UK (CRUK), has collaborated to drive cancer drug development using the former’s PEDAL platform. Predictive Oncology stated that its PEDAL platform makes high-confidence drug response predictions.

Research 130

Research Clinical Development Drugs Development 130

Bio Pharma Dive

MARCH 25, 2024

The agency wants Regeneron to make more progress with a confirmatory trial before clearing odronextamab, a “bispecific” antibody being developed for multiple blood cancers.

Antibody 280

Antibody Drugs Trials Development 280

Bio Pharma Dive

OCTOBER 9, 2023

Oncology manufacturers can improve access by using claims, labs, pathway and policy data to address misalignment.

Manufacturing 148

Manufacturing 148

Pharmaceutical Technology

FEBRUARY 13, 2023

This collaboration aims to use the global SOPHiA DDM platform, a cloud-native platform of SOPHiA GENETICS, and multimodal algorithmic capabilities for AstraZeneca’s oncology portfolio. The post SOPHiA GENETICS and AstraZeneca partner for oncology drugs development appeared first on Pharmaceutical Technology.

Genetics 130

Genetics Development Drugs Genome 130

Pharmaceutical Technology

NOVEMBER 13, 2023

An upcoming two-day event will host talks on the impact of new technology on oncology trials and smaller biotechs.

Trials 130

Trials 130

Pharmaceutical Technology

MARCH 4, 2024

In late 2023, the Medicines and Healthcare products Regulatory Agency approved Vertex’s Casgevy, which became the inaugural clustered regularly interspaced short palindromic repeats (CRISPR)-based drug for the haematological indications beta thalassemia and sickle cell disease (SCD).

Medicine 278

Medicine Production Drugs 278

Bio Pharma Dive

OCTOBER 1, 2022

The “Evolution and Innovation in Oncology Therapeutics Development” podcast series explores the role of multi-biomarkers in precision oncology.

Development 130

Development 130